February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Highlights by Sakditad Saowapa from ASCO GU25
Feb 16, 2025, 19:04

Highlights by Sakditad Saowapa from ASCO GU25

The 2025 ASCO Genitourinary Cancers Symposium is currently taking place from February 13-15 at Moscone West in San Francisco. This event is showcasing the latest research and best practices in genitourinary (GU) cancer care, with expert talks and engaging discussions. Attendees are experiencing a comprehensive program that includes keynote presentations, panel discussions, and interactive sessions focused on advancements in the diagnosis, treatment, and patient management of GU cancers.

The symposium provides healthcare professionals with an invaluable opportunity to engage with leading researchers, gain insights into emerging therapies, and enhance their clinical practices. It is co-sponsored by the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the Society of Urologic Oncology.

Sakditad Saowapa, Resident Physician at Texas Tech University Health Sciences Center, shared about this conference on Social Media:

Ready to rock the last day of GU25

“Ready to rock the last day of GU25!

Let’s make it fun and refreshing at the ASCO Genitourinary Cancers Symposium for renal cancer day.”

Highlights by Sakditad Saowapa from ASCO GU25

PSA rises increase the chance of true positives

“PSMA PET scans can be tricky with false positives, but faster PSA rises increase the chance of true positives.

Expected spread patterns usually hold true, and no PSMA agent stands out yet. Standardized reporting helps!”

Highlights by Sakditad Saowapa from ASCO GU25

The latest findings on racial disparities 

“Join me at poster board C4 for GU25 to discuss the latest findings on racial disparities in secondary metastasis in bladder cancer patients.

African American patients had higher odds of lung metastasis (OR 1.22, 95% CI: 1.11-1.34) and liver metastasis (OR 1.19, 95% CI: 1.05-1.35) compared to White patients.

Asian patients had higher odds of bone metastasis (OR 1.38, 95% CI: 1.13-1.68) and brain metastasis (OR 1.46, 95% CI: 1.03-2.07) compared to White patients.”

Highlights by Sakditad Saowapa from ASCO GU25

PSMA PET vs. Conventional Imaging

“PSMA PET vs. Conventional Imaging:

PSMA PET offers superior accuracy, sensitivity, and specificity for detecting metastases in high-risk patients in RCT, while 18F-Fluciclovine is approved for biochemical recurrent disease detection, not initial staging.

WB-MRI excels in bone lesion detection but is less sensitive for nodal lesions compared to PSMA imaging.

Case-Based Session: Evolving Landscape of the Management of Oligometastatic Disease (Prostate Cancer).”

Highlights by Sakditad Saowapa from ASCO GU25

ENRT with MDT for involved LNs is a game-changer

“Breaking News! At ASCO GU25, ASCO revealed that adding MDT to IAS not only extends off-treatment periods but also hints at a promising future with intensified ADT and ARPIs!

Plus, ENRT with MDT for involved LNs is a game-changer, well-tolerated and showing potential. Stay tuned for more from PEACE V!”

Highlights by Sakditad Saowapa from ASCO GU25

Ab311 by Dr. Robert J. Thomas

“Super interesting session on gut health and prostate cancer!

Ab311 by Dr. Robert J. Thomas: The study shows that boosting phytochemical-rich foods with a specific supplement slows PSA progression and improves urinary symptoms.

The world’s first robust RCT indicates a lactobacillus supplement further reduces PSA progression.

Exciting findings with longer-term follow-up needed for low-risk men. Self-help nutrition advice welcomed!”

Highlights by Sakditad Saowapa from ASCO GU25

Driving Science to improve Patient-Centered Care

Creative Innovation: Driving Science to improve Patient-Centered Care by Bill Dahut!

At general session 3rd floor Moscone West San Francisco.”

Highlights by Sakditad Saowapa from ASCO GU25